| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Kerry Hunter, Christian Hölsche. Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis. BMC neuroscience. vol 13. 2012-08-10. PMID:22443187. |
they facilitate insulin signalling via the glp-1 receptor (glp-1r). |
2012-08-10 |
2023-08-12 |
Not clear |
| Henning Beck-Nielse. [Glucagon-like peptide 1 analogues in the treatment of type 2 diabetes mellitus]. Ugeskrift for laeger. vol 174. issue 23. 2012-08-08. PMID:22673382. |
compared with sulfonylurea and insulin, the advantage of glp-1 analogues is not only that they rarely induce hypoglycaemia, but also that body weight is reduced. |
2012-08-08 |
2023-08-12 |
Not clear |
| David Porter, Emilie Faivre, Peter R Flatt, Christian Hölscher, Victor A Gaul. Actions of incretin metabolites on locomotor activity, cognitive function and in vivo hippocampal synaptic plasticity in high fat fed mice. Peptides. vol 35. issue 1. 2012-08-07. PMID:22465882. |
therefore, the present study investigated effects of glp-1(9-36)amide and gip(3-42) on locomotor activity, cognitive function and hippocampal synaptic plasticity in mice with diet-induced obesity and insulin resistance. |
2012-08-07 |
2023-08-12 |
mouse |
| David Porter, Emilie Faivre, Peter R Flatt, Christian Hölscher, Victor A Gaul. Actions of incretin metabolites on locomotor activity, cognitive function and in vivo hippocampal synaptic plasticity in high fat fed mice. Peptides. vol 35. issue 1. 2012-08-07. PMID:22465882. |
high-fat fed swiss to mice treated with glp-1(9-36)amide, gip(3-42) or exendin(9-39)amide (twice-daily for 60 days) did not exhibit any changes in bodyweight, non-fasting plasma glucose and plasma insulin concentrations or glucose tolerance compared with high-fat saline controls. |
2012-08-07 |
2023-08-12 |
mouse |
| John R Ussher, Daniel J Drucke. Cardiovascular biology of the incretin system. Endocrine reviews. vol 33. issue 2. 2012-08-02. PMID:22323472. |
glucagon-like peptide-1 (glp-1) is an incretin hormone that enhances glucose-stimulated insulin secretion and exerts direct and indirect actions on the cardiovascular system. |
2012-08-02 |
2023-08-12 |
human |
| Joanne Selway, Roberto Rigatti, Nina Storey, Jing Lu, Gary B Willars, Terence P Herber. Evidence that Ca2+ within the microdomain of the L-type voltage gated Ca2+ channel activates ERK in MIN6 cells in response to glucagon-like peptide-1. PloS one. vol 7. issue 3. 2012-08-02. PMID:22412973. |
glucagon like peptide-1 (glp-1) is released from intestinal l-cells in response to nutrient ingestion and acts upon pancreatic β-cells potentiating glucose-stimulated insulin secretion and stimulating β-cell proliferation, differentiation, survival and gene transcription. |
2012-08-02 |
2023-08-12 |
Not clear |
| Saahir Khan, Shantanu Sur, Christina J Newcomb, Elizabeth A Appelt, Samuel I Stup. Self-assembling glucagon-like peptide 1-mimetic peptide amphiphiles for enhanced activity and proliferation of insulin-secreting cells. Acta biomaterialia. vol 8. issue 5. 2012-07-31. PMID:22342354. |
these limitations could potentially be overcome by relying on the activity of glucagon-like peptide 1 (glp-1), which acts on β-cells to promote insulin release, proliferation and survival. |
2012-07-31 |
2023-08-12 |
rat |
| Yasuhisa Mori, Takao Ohtsuka, Kosuke Tsutsumi, Takaharu Yasui, Junji Ueda, Shunichi Takahata, Masafumi Nakamura, Masao Tanak. Different incretin responses after pancreatoduodenectomy and distal pancreatectomy. Pancreas. vol 41. issue 3. 2012-07-31. PMID:22422137. |
glucagon-like peptide-1 (glp-1) and glucose-dependent insulinotropic polypeptide (gip) are known as incretins to stimulate insulin secretion. |
2012-07-31 |
2023-08-12 |
Not clear |
| H Lan, H V Lin, C F Wang, M J Wright, S Xu, L Kang, K Juhl, J A Hedrick, T J Kowalsk. Agonists at GPR119 mediate secretion of GLP-1 from mouse enteroendocrine cells through glucose-independent pathways. British journal of pharmacology. vol 165. issue 8. 2012-07-27. PMID:22029751. |
the g protein-coupled receptor 119 (gpr119) mediates insulin secretion from pancreatic β cells and glucagon-like peptide 1 (glp-1) release from intestinal l cells. |
2012-07-27 |
2023-08-12 |
mouse |
| H Lan, H V Lin, C F Wang, M J Wright, S Xu, L Kang, K Juhl, J A Hedrick, T J Kowalsk. Agonists at GPR119 mediate secretion of GLP-1 from mouse enteroendocrine cells through glucose-independent pathways. British journal of pharmacology. vol 165. issue 8. 2012-07-27. PMID:22029751. |
while gpr119-mediated insulin secretion is glucose dependent, it is not clear whether or not gpr119-mediated glp-1 secretion similarly requires glucose. |
2012-07-27 |
2023-08-12 |
mouse |
| Thomas Forst, Matthias M Weber, Andreas Pfützne. Cardiovascular benefits of GLP-1-based herapies in patients with diabetes mellitus type 2: effects on endothelial and vascular dysfunction beyond glycemic control. Experimental diabetes research. vol 2012. 2012-07-26. PMID:22577369. |
beside the effects of glp-1 on insulin secretion, glucagon secretion, and gastrointestinal motility, recent studies suggested a couple of direct cardiovascular effects of glp-1-based therapies. |
2012-07-26 |
2023-08-12 |
Not clear |
| Jacob Sivertsen, Jaya Rosenmeier, Jens J Holst, Tina Vilsbøl. The effect of glucagon-like peptide 1 on cardiovascular risk. Nature reviews. Cardiology. vol 9. issue 4. 2012-07-24. PMID:22290234. |
glucagon-like peptide 1 (glp-1) is an incretin hormone responsible for amplification of insulin secretion when nutrients are given orally, as opposed to intravenously, and it retains its insulinotropic activity in patients with type 2 diabetes mellitus. |
2012-07-24 |
2023-08-12 |
Not clear |
| Yvan Gosmain, Liora S Katz, Mounia Heddad Masson, Claire Cheyssac, Caroline Poisson, Jacques Philipp. Pax6 is crucial for β-cell function, insulin biosynthesis, and glucose-induced insulin secretion. Molecular endocrinology (Baltimore, Md.). vol 26. issue 4. 2012-07-19. PMID:22403172. |
we also demonstrated that pax6 knockdown led to decreases in insulin cell content, in insulin processing, and a specific defect of glucose-induced insulin secretion as well as a significant reduction of glp-1 action in primary β-cells. |
2012-07-19 |
2023-08-12 |
rat |
| S ThanThan, T Saito, S Yannaing, H Zhao, K Nakashima, H Kuwayam. Glucagon-like peptide-1 inhibits insulinotropic effects of oxyntomodulin and glucagon in cattle. Domestic animal endocrinology. vol 42. issue 3. 2012-07-17. PMID:22154917. |
in experiment 1, effects of glucagon and glp-1 on plasma insulin and glucose were investigated in 10-mo-old holstein steers (347 ± 8 kg, n = 8) under normoglycemic conditions. |
2012-07-17 |
2023-08-12 |
cattle |
| Giuseppe Paolisso, Matteo Monami, Raffaele Marfella, Maria Rosaria Rizzo, Edoardo Mannucc. Dipeptidyl peptidase-4 inhibitors in the elderly: more benefits or risks? Advances in therapy. vol 29. issue 3. 2012-07-16. PMID:22411425. |
moreover, hypoglycemia is a frequent side effect of therapeutic treatment with insulin, sulfonylureas or glinides, while other treatments (metformin, acarbose, thiazolidinediones, glucagon-like peptide-1 [glp-1] receptor agonists, and dipeptidyl peptidase-4 [dpp4] inhibitors) are capable of reducing hyperglycemia without inducing hypoglycemia. |
2012-07-16 |
2023-08-12 |
human |
| Giuseppe Paolisso, Matteo Monami, Raffaele Marfella, Maria Rosaria Rizzo, Edoardo Mannucc. Dipeptidyl peptidase-4 inhibitors in the elderly: more benefits or risks? Advances in therapy. vol 29. issue 3. 2012-07-16. PMID:22411425. |
available options include sulfonylureas, meglitinides, alfa-glucosidase inhibitors, pioglitazone, insulin, glp-1 receptor agonists, and dpp-4 inhibitors. |
2012-07-16 |
2023-08-12 |
human |
| Giuseppe Paolisso, Matteo Monami, Raffaele Marfella, Maria Rosaria Rizzo, Edoardo Mannucc. Dipeptidyl peptidase-4 inhibitors in the elderly: more benefits or risks? Advances in therapy. vol 29. issue 3. 2012-07-16. PMID:22411425. |
these hormones potentiate the acute effects of glucose on pancreatic alfa and beta cells, thus stimulating insulin secretion, and only glp-1 inhibits glucagon secretion in a glucose-dependent manner (that is, only when glucose levels are increased); as a result, they reduce hyperglycemia with virtually no hypoglycemic risk. |
2012-07-16 |
2023-08-12 |
human |
| Michelle Kan, GuiFang Guo, Bhagat Singh, Vandana Singh, Douglas W Zochodn. Glucagon-like peptide 1, insulin, sensory neurons, and diabetic neuropathy. Journal of neuropathology and experimental neurology. vol 71. issue 6. 2012-07-16. PMID:22588388. |
like insulin, glucagon-like peptide 1 (glp-1) may have direct trophic actions on the nervous system, but its potential role in supporting diabetic sensory neurons is uncertain. |
2012-07-16 |
2023-08-12 |
mouse |
| Michelle Kan, GuiFang Guo, Bhagat Singh, Vandana Singh, Douglas W Zochodn. Glucagon-like peptide 1, insulin, sensory neurons, and diabetic neuropathy. Journal of neuropathology and experimental neurology. vol 71. issue 6. 2012-07-16. PMID:22588388. |
taken together, these results suggest that although glp-1 agonists and insulin alone are insufficient to reverse all features of diabetic neuropathy, in combination, they might benefit some aspects of established diabetic neuropathy. |
2012-07-16 |
2023-08-12 |
mouse |
| Riitta Törrönen, Essi Sarkkinen, Tarja Niskanen, Niina Tapola, Kyllikki Kilpi, Leo Niskane. Postprandial glucose, insulin and glucagon-like peptide 1 responses to sucrose ingested with berries in healthy subjects. The British journal of nutrition. vol 107. issue 10. 2012-07-10. PMID:21929838. |
the present study investigated the postprandial glucose, insulin and glucagon-like peptide 1 (glp-1) responses to sucrose ingested with berries, in comparison with a similar sucrose load without berries. |
2012-07-10 |
2023-08-12 |
human |